BMO Capital raised the firm’s price target on Eli Lilly to $1,101 from $1,001 and keeps an Outperform rating on the shares. The firm cites the company’s Q2 earnings beat and the “exceptional execution” on the largest BioPharma manufacturing expansion since the pandemic, the analyst tells investors in a research note. Commercial excellence and nimbleness in the U.S. market is becoing the expectations from Lilly after its two healthy guidance raises in a row, BMO added.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- LLY Earnings: Eli Lilly Reports Impressive Q2 Results; Huge Revenue Increase
- Options Volatility and Implied Earnings Moves Today, August 08, 2024
- Eli Lilly raises FY24 EPS view to $16.10-$16.60 from $13.50-$14.00
- Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion
- Eli Lilly reports Q2 EPS $3.92, consensus $2.60